305 related articles for article (PubMed ID: 12396973)
1. [Galantamine: a novel cholinergic agent for Alzheimer's disease].
Olazarán J; García G
Neurologia; 2002 Oct; 17(8):429-36. PubMed ID: 12396973
[TBL] [Abstract][Full Text] [Related]
2. Galantamine in Alzheimer's disease.
Razay G; Wilcock GK
Expert Rev Neurother; 2008 Jan; 8(1):9-17. PubMed ID: 18088197
[TBL] [Abstract][Full Text] [Related]
3. Galantamine: a review of its use in Alzheimer's disease and vascular dementia.
Corey-Bloom J
Int J Clin Pract; 2003 Apr; 57(3):219-23. PubMed ID: 12723727
[TBL] [Abstract][Full Text] [Related]
4. Update on Alzheimer drugs (galantamine).
Raskind MA
Neurologist; 2003 Sep; 9(5):235-40. PubMed ID: 12971834
[TBL] [Abstract][Full Text] [Related]
5. Effects of galantamine in patients with mild Alzheimer's disease.
Orgogozo JM; Small GW; Hammond G; Van Baelen B; Schwalen S
Curr Med Res Opin; 2004 Nov; 20(11):1815-20. PubMed ID: 15537482
[TBL] [Abstract][Full Text] [Related]
6. Galantamine: use in Alzheimer's disease and related disorders.
Bullock R
Expert Rev Neurother; 2004 Mar; 4(2):153-63. PubMed ID: 15853556
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of galantamine in the treatment of Alzheimer's disease: comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure.
Mintzer JE; Kershaw P
Int J Geriatr Psychiatry; 2003 Apr; 18(4):292-7. PubMed ID: 12673604
[TBL] [Abstract][Full Text] [Related]
8. Galantamine for Alzheimer's disease.
Prvulovic D; Hampel H; Pantel J
Expert Opin Drug Metab Toxicol; 2010 Mar; 6(3):345-54. PubMed ID: 20113148
[TBL] [Abstract][Full Text] [Related]
9. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
Grossberg GT; Edwards KR; Zhao Q
J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
[TBL] [Abstract][Full Text] [Related]
10. Galantamine: new preparation. The fourth cholinesterase inhibitor for Alzheimer's disease.
Prescrire Int; 2001 Dec; 10(56):180-1. PubMed ID: 11824442
[TBL] [Abstract][Full Text] [Related]
11. The pharmacological rationale for treating vascular dementia with galantamine (Reminyl).
Maelicke A
Int J Clin Pract Suppl; 2001 May; (120):24-8. PubMed ID: 11406923
[TBL] [Abstract][Full Text] [Related]
12. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
Chu LW; Yik PY; Mok W; Chung CP
Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606
[TBL] [Abstract][Full Text] [Related]
13. [Nicotinic Receptor, galantamine and Alzheimer disease].
Arroyo G; Aldea M; Fuentealba J; García AG
Rev Neurol; 2002 Jun 1-15; 34(11):1057-65. PubMed ID: 12134305
[TBL] [Abstract][Full Text] [Related]
14. Cholinesterase inhibitors in the treatment of dementia.
Ellis JM
J Am Osteopath Assoc; 2005 Mar; 105(3):145-58. PubMed ID: 15863734
[TBL] [Abstract][Full Text] [Related]
15. [Observational study on safety, tolerability and effectiveness of galantamine in patients with mild to moderately severe Alzheimer's disease].
Blesa R; García Ribas G; Galdós L; Olascoaga J; Amer G; Marey López J; Barquero M; Marsall C; Ezpeleta D
Neurologia; 2006; 21(6):289-96. PubMed ID: 16799903
[TBL] [Abstract][Full Text] [Related]
16. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.
Alexopoulos GS; Jeste DV; Chung H; Carpenter D; Ross R; Docherty JP
Postgrad Med; 2005 Jan; Spec No():6-22. PubMed ID: 17203561
[TBL] [Abstract][Full Text] [Related]
17. The effect of Galantamine on sleep quality in Thai Alzheimer's disease patients.
Chankrachang S; Senanarong V; Poungvarin N; Phanthumchinda K; Tavichachart N; Praditsuwan R; Nidhinandana S
J Med Assoc Thai; 2008 Sep; 91(9):1343-9. PubMed ID: 18843862
[TBL] [Abstract][Full Text] [Related]
18. Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
Prescrire Int; 2006 Jun; 15(83):103-6. PubMed ID: 16764099
[TBL] [Abstract][Full Text] [Related]
19. Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease.
Geerts H; Grossberg GT
J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):8S-16S. PubMed ID: 16809810
[TBL] [Abstract][Full Text] [Related]
20. The effects of galantamine treatment on caregiver time in Alzheimer's disease.
Sano M; Wilcock GK; van Baelen B; Kavanagh S
Int J Geriatr Psychiatry; 2003 Oct; 18(10):942-50. PubMed ID: 14533127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
